OGT is developing innovative products and services to enable researchers to efficiently detect mutations in cancer samples.
The first approach has been funded by the UK Technology Strategy Board’s Stratified Medicine Programme where OGT is working with leading UK NHS laboratories and clinical software companies to produce an integrated service based on Next Generation Sequencing to detect clinically relevant mutations in breast, lung, colorectal and prostate cancer. The approach requires development of optimised sample preparation and enrichment technologies along with seamless analysis and databasing solutions.
The second approach is the development of a proprietary technology to detect mutations directly on a microarray. This uses the ligation of labelled library oligonucleotides to the oligonucleotide probes on an array to detect the mutations. In addition to mutation detection the technology can also be used for resequencing genes and exons as well as SNP genotyping, with high discrimination between the two alleles.
Contact us for more information.